Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
Heart Disease in Lupus: The Impact of Rural Residence on Hospitalizations
Heart Disease in Lupus: The Impact of Rural Residence on Hospitalizations
Clinical Perspectives on Prioritizing LDL-C Management After a Recent Coronary Event
Clinical Perspectives on Prioritizing LDL-C Management After a Recent Coronary Event
Prioritizing LDL-C Reduction for Established CVD Patients in Primary Care
Prioritizing LDL-C Reduction for Established CVD Patients in Primary Care
Exploring the Risk of HF Hospitalization or CV Death in HFrEF Patients and a Potential Treatment Option
Exploring the Risk of HF Hospitalization or CV Death in HFrEF Patients and a Potential Treatment Option
Confronting the Complexities of Reaching LDL-C Thresholds in Patients with Primary Hyperlipidemia
Confronting the Complexities of Reaching LDL-C Thresholds in Patients with Primary Hyperlipidemia
Primary Hyperlipidemia: Fresh look at an LDL-C Therapy and its Long-Term Data
Primary Hyperlipidemia: Fresh look at an LDL-C Therapy and its Long-Term Data
Overcoming Real World Challenges of LDL-C Management: Looking Beyond Statin Therapy
Overcoming Real World Challenges of LDL-C Management: Looking Beyond Statin Therapy
eurekalert.org
cleveland.com
medicalxpress.com
news.virginia.edu
news-medical.net
healthline.com
